Viking Therapeutics prices $250M public offering of 17.2M shares at $14.50

Viking Therapeutics, Inc.

Gross proceeds ~$250M from 17.2M shares at $14.50; underwriters have 30-day option for 2.6M additional shares.
Net proceeds to fund development programs VK2809, VK2735, VK0214 and for general R&D and working capital.
Lead bookrunners: William Blair and Raymond James; co-managers: BTIG, Oppenheimer, H.C. Wainwright, Maxim, Roth, Laidlaw.
Offering expected to close on April 3, 2023, subject to customary closing conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

Viking Therapeutics, Inc. entered into Underwriting Agreement with William Blair & Company, L.L.C., as representative of the several underwriters valued at approximately $250.0 million (effective 2023-03-29).

Action: entry
Agreement: underwriting
Counterparty: William Blair & Company, L.L.C., as representative of the several underwriters
Value: approximately $250.0 million
Effective: 2023-03-29

Exact text from the filing

On March 29, 2023, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C. (the “Representative”), as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 17,242,000 shares of the Company’s common stock (“Common Stock”).

View on SEC.gov

Browse all material agreements →

Viking Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-011443

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.